Genelux (GNLX) Depreciation and Depletion (2022 - 2026)
Genelux's (GNLX) quarterly Depreciation and Depletion came in at $9000.0 in Q1 2026, down 84.75% year-on-year from $59000.0 in Q1 2025, and down 85.0% quarter-over-quarter from $60000.0 in Q4 2025.
Genelux (GNLX) Depreciation and Depletion (2022 - 2026) Analysis & Trends
Genelux's Depreciation and Depletion history runs 5 years deep, the most recent figure standing at $9000.0 for Q1 2026.
- On a quarterly basis, Depreciation and Depletion fell 84.75% year-over-year to $9000.0 in Q1 2026; TTM through Mar 2026 was $193000.0, a 8.1% decrease from a year earlier, with the FY2025 full-year figure at $244000.0, up 3.83% from the prior year.
- Depreciation and Depletion fell to $9000.0 in Q1 2026 per GNLX's latest filing, from $60000.0 in the prior quarter.
- Across five years, Depreciation and Depletion topped out at $138000.0 in Q1 2022 and bottomed at $9000.0 in Q1 2026.
- The 5-year median for Depreciation and Depletion is $63000.0 (2025), against an average of $84133.3.
- Across the five-year window, Depreciation and Depletion soared 65.79% in 2025 and tumbled 84.75% in 2026, its largest moves.
- Year by year, Depreciation and Depletion stood at $138000.0 in 2022, then sank by 31.16% to $95000.0 in 2023, then plunged by 40.0% to $57000.0 in 2024, then advanced by 5.26% to $60000.0 in 2025, then tumbled by 85.0% to $9000.0 in 2026.
- Per Business Quant, the three latest GNLX Depreciation and Depletion figures stand at $9000.0 (Q1 2026), $60000.0 (Q4 2025), and $61000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,792.52 Bn | 1,792.46 Bn | - | - |
| 2 | Akari Therapeutics | 999.95 Bn | 999.95 Bn | - | - |
| 3 | BeOne Medicines | 475.97 Bn | 471.17 Bn | 1.35 Bn | 39.39 Mn |
| 4 | Vertex Pharmaceuticals | 124.91 Bn | 117.66 Bn | 2.59 Bn | - |
| 5 | Regeneron Pharmaceuticals | 72.31 Bn | 63.56 Bn | 3.31 Bn | - |
| 6 | Belite Bio | 62.01 Bn | 62.01 Bn | - | - |
| 7 | Argenx Se | 54.23 Bn | 49.04 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.31 Bn | 35.30 Bn | 959.66 Mn | - |
| 9 | Revolution Medicines | 36.16 Bn | 36.16 Bn | - | 2.20 Mn |
| 10 | Genelux | 128.04 Mn | 128.04 Mn | - | 9,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9,000.00 |
| Mar 31, 2026 | 9,000.00 |
| Dec 31, 2025 | 60,000.00 |
| Dec 31, 2025 | 60,000.00 |
| Sep 30, 2025 | 61,000.00 |
| Sep 30, 2025 | 61,000.00 |
| Jun 30, 2025 | 63,000.00 |
| Jun 30, 2025 | 63,000.00 |
| Mar 31, 2025 | 59,000.00 |
| Mar 31, 2025 | 59,000.00 |
| Dec 31, 2024 | 57,000.00 |
| Dec 31, 2024 | 57,000.00 |
| Sep 30, 2024 | 56,000.00 |
| Sep 30, 2024 | 56,000.00 |
| Jun 30, 2024 | 38,000.00 |
| Jun 30, 2024 | 38,000.00 |
| Mar 31, 2024 | 84,000.00 |
| Mar 31, 2024 | 84,000.00 |
| Dec 31, 2023 | 95,000.00 |
| Dec 31, 2023 | 95,000.00 |